Cellromax Science

471820 · KOSDAQ · ₩471820 · 셀로맥스사이언스

₩3,965▼ ₩100 (2.46%)End-of-day · Oct 29, 2026 · End-of-day prices.
Trade
Alert me

Valuation model · Discounted cash flow (DCF)

We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.

Fair value per share

₩3,952

vs the current price (₩3,965)

Enterprise value
₩40B
Equity value
₩45B
WACC
7.4%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.

Bear / Base / Bull

Bear
₩2,738
−30.9%
Base
₩3,952
−0.3%
Bull
₩5,992
+51.1%

Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.

Assumptions

Sign in to change the assumptions and see the results update. Sign in

Cycle options

Margin path

Every year uses the cycle-average margin (16.4%).

Revenue growth

  • 2.6%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (2.6% a year, annual reports), fading to 3% by year 5.

  • 2.7%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (2.6% a year, annual reports), fading to 3% by year 5.

  • 2.8%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (2.6% a year, annual reports), fading to 3% by year 5.

  • 2.9%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (2.6% a year, annual reports), fading to 3% by year 5.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (2.6% a year, annual reports), fading to 3% by year 5.

Business

  • 16.4%

    Operating profit as a share of revenue.

    Default: through-the-cycle average of the last 12 months and the last 2 annual reports' operating margins.

  • 27.5%

    Share of operating profit paid as corporate tax.

    Default: Korea's top corporate tax rate (25%) plus 10% local income tax.

  • 5.4%

    The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).

    Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).

  • 6.8%

    Money spent on factories, equipment, software and other long-term assets (% of revenue).

    Default: average of the last 2 annual reports (cash flow statements; equipment and intangibles).

  • 40%

    Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.

    Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 2 years.

Discount rate

  • 2%

    How fast cash flows keep growing every year after year 5.

    Default: about Korea's long-run inflation plus real growth.

  • 4.08%

    Yield on Korea's 10-year government bond: the return with almost no risk.

    Default: Korea Treasury Bond 10-year yield on 2026-10-29.

  • 0.6

    How much the share moves when the market moves: 1 means just like the market.

    Default: 98 weeks of weekly returns against KOSPI (official index); raw beta 0.18, adjusted toward 1 and kept between 0.6 and 2.0.

  • 5.5%

    The extra return investors want for owning shares instead of bonds.

    Default: a typical premium for Korean shares.

  • 5.58%

    The interest rate the company would pay to borrow.

    Default: the 10-year yield plus a 1.5% credit spread.

Starting point

Revenue (TTM to H1 2026)
₩20B
Net debt (borrowings and leases − cash and deposits)
−₩5.1B
Shares
11,302,879
Share price
₩3,965
Market cap
₩45B

TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.

Past years and projection

Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.

FY2024FY2025Year 1Year 2Year 3Year 4Year 5
Revenue₩22B₩22B₩20B₩21B₩21B₩22B₩23B
Growth—2.6%2.6%2.7%2.8%2.9%3.0%
EBIT₩5.5B₩2.8B₩3.3B₩3.4B₩3.5B₩3.6B₩3.7B
EBIT margin25.4%12.8%16.4%16.4%16.4%16.4%16.4%
After-tax EBIT₩4B₩2.1B₩2.4B₩2.5B₩2.5B₩2.6B₩2.7B
+ Depreciation——₩1.1B₩1.1B₩1.1B₩1.2B₩1.2B
− Capital spending₩2.8B₩179M₩1.4B₩1.4B₩1.4B₩1.5B₩1.5B
− Working capital—−₩3B₩204M₩217M₩231M₩246M₩262M
Free cash flow——₩1.9B₩1.9B₩2B₩2B₩2.1B
Discount factor——0.9310.8670.8080.7520.700
Present value——₩1.8B₩1.7B₩1.6B₩1.5B₩1.5B

Terminal value ₩45B, worth ₩32B today: 80% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.

Sensitivity

Fair value per share as two inputs change; the middle is the current case.

WACC ↓ · Terminal growth →1.0%1.5%2.0%2.5%3.0%
6.4%₩4,186₩4,450₩4,772₩5,177₩5,702
6.9%₩3,857₩4,067₩4,320₩4,630₩5,018
7.4%₩3,580₩3,750₩3,952₩4,194₩4,491
7.9%₩3,343₩3,483₩3,647₩3,840₩4,072
8.4%₩3,139₩3,255₩3,389₩3,546₩3,731

Now (TTM)

Market cap
₩45B
Enterprise value
₩39B
P/E
11.8×
P/B
1.0×
P/S
2.3×
EV/EBITDA
—
Dividend yield
4.7%

Over time (at each year end)

20252024
Price₩6,500₩4,915
Market cap₩73B₩56B
P/E24.8×14.6×
P/B1.6×1.2×
P/S3.3×2.6×
EV/EBITDA——
Dividend yield2.8%3.4%

Versus similar companies

CompanyP/EP/BP/SEV/EBITDADividend yield
Cellromax Science11.8×1.0×2.3×—4.7%
Samyang Foods17.6×5.6×3.1×—0.4%
Orion10.6×1.1×1.2×5.3×3.1%
CJ Cheiljedang—0.3×0.1×—3.5%
Nongshim12.0×0.8×0.6×—1.5%
Otoki17.3×0.6×0.3×—2.9%
Hite Jinro23.2×0.9×0.4×6.4×4.5%
Similar companies (median)17.3×0.9×0.5×5.8×3.0%

Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.

Also known as: Cellromax Science / 셀로맥스사이언스 / 471820 / KRX:471820

Source: KRX statistical information